AL Amyloidosis Market Report 2025

This AL Amyloidosis market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The AL amyloidosis market size has grown rapidly in recent years. It will grow from $3.11 billion in 2024 to $3.52 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth during the historic period can be attributed to increasing awareness among healthcare providers about AL amyloidosis, a rising incidence of the condition, the aging population, the expansion of diagnostic centers, and advancements in cardiac imaging.

The AL amyloidosis market size is expected to see rapid growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 13%. The expected growth in the forecast period is driven by factors such as the rise in mutations in blood cell DNA, the expansion of healthcare infrastructure, a growing incidence of multiple myeloma, the introduction of combination therapies, and an increased use of high-dose chemotherapy. Key trends during this period include advancements in diagnostic techniques, technological innovations in drug delivery, improvements in blood tests, the development of targeted therapies, and the integration of artificial intelligence (AI) in diagnosis.

The rising incidence of plasma cell disorders is expected to drive the growth of the AL amyloidosis market. Plasma cell disorders are conditions in which abnormal plasma cells produce excessive or irregular antibodies, potentially causing organ damage. Factors such as an aging population, increased life expectancy, and advancements in diagnostic technologies are contributing to the increasing incidence of these disorders. AL amyloidosis, which results from plasma cell disorders, specifically arises from the overproduction of abnormal light chain proteins. This leads to the accumulation of amyloid deposits in organs and tissues, further exacerbating the effects of plasma cell dyscrasias. For example, in August 2024, The American Cancer Society (ACS) reported that around 35,780 new cases of multiple myeloma are expected to be diagnosed in 2024, with 19,520 in men and 16,260 in women, and approximately 12,540 deaths projected, including 7,020 men and 5,520 women. As a result, the growing prevalence of plasma cell disorders is driving the expansion of the AL amyloidosis market.

Companies in the AL amyloidosis market are focusing on developing innovative therapies, such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, to enhance treatment efficacy and patient outcomes. BCMA-directed CAR T-cell therapy is an advanced immunotherapy that involves modifying a patient's T cells to target and attack BCMA on the surface of cancer cells, particularly in multiple myeloma. For instance, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for NXC-201, a next-generation CAR-T cell therapy for the treatment of the life-threatening blood disorder AL amyloidosis. NXC-201 has shown promising results in clinical trials, with a 100% hematologic response rate and organ improvements in patients who had not responded to previous treatments.

In November 2024, Stand Up To Cancer (SU2C), a US-based non-profit organization, partnered with Johnson & Johnson Inc. to advance research on novel treatments for AL amyloidosis. This collaboration aims to explore the combination of teclistamab and daratumumab as a treatment for AL amyloidosis, a rare and challenging disease, to improve therapeutic options for affected patients. Johnson & Johnson Inc., a US-based healthcare company, specializes in providing treatments for AL amyloidosis.

Major players in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, and Attralus Inc.

North America was the largest region in the AL amyloidosis market in 2024. The regions covered in AL amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the AL amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

AL Amyloidosis is a rare and serious condition where abnormal proteins, known as light chains, are produced by plasma cells in the bone marrow. These light chains misfold and form amyloid fibrils, which then accumulate in various organs and tissues, impairing their function. The heart, kidneys, liver, and nervous system are commonly affected. Symptoms depend on the organs involved but often include fatigue, swelling, shortness of breath, numbness, and organ dysfunction.

The main treatment options for AL amyloidosis include therapies such as chemotherapy, supportive care, surgery, stem cell transplants, and targeted therapy. Chemotherapy uses potent drugs to target amyloid deposits, with the goal of reducing symptoms and improving survival. These drugs include transthyretin transport inhibitors, immunomodulatory drugs, monoclonal antibodies, and proteasome inhibitors. They can be administered intravenously or orally. In terms of distribution, these treatments are typically available through hospital pharmacies, retail pharmacies, and online pharmacies, ensuring patients can access the medications based on their needs and convenience.

The AL amyloidosis market research report is one of a series of new reports that provides AL amyloidosis market statistics, including the AL amyloidosis industry global market size, regional shares, competitors with the AL amyloidosis market share, detailed AL amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the AL amyloidosis industry. This AL amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The AL amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and follow-up services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The AL amyloidosis market also includes sales of proteasome inhibitors, monoclonal antibodies, diagnostic tests, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.